Cefpirome

Susceptible infections

Intravenous Susceptible infections Adult: As sulfate: 1-2 g every 12 hrly

Renal impairment: Loading dose: 1-2 g followed by a maintenance dose adjusted according to CrCl. CrCl (ml/min) 20-50 0.5-1 g bid. 5-20 0.5-1 g once daily. <5 (in hemodialysis patients) 0.5 or 1 g once daily with half-dose after each dialysis session.

IV Administration Administer by IV inj over 3-5 min, OR By intermittent infusion over 20-30 min

Hypersensitivity; porphyria.

Allergy to penicillin or to cephalosporins; renal impairment, monitor renal and haematological status; pregnancy and lactation. Lactation: excreted in breast milk; unsure if safe; do not use

Not Classi

Reduced clearance with probenecid.

<1% Colitis,Diarrhea,Dyspnea,Headache,Phlebitis,Rash,Vaginitis,Vomiting Potentially Fatal: Pseudomembranous colitis.

Cefpirome binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.